News | Stents Peripheral | March 02, 2017

First Patient Treated in TOBA II BTK Clinical Trial of Tack Endovascular System

Trial studies combination of Intact Vascular's Tack Endovascular System and standard balloon angioplasty in the treatment of patients with critical limb ischemia (CLI)

TOBA II BTK clinical trial, Intact Vascular, Tack Endovascular System, CLI, critical limb ischemia, first patient treated

March 2, 2017 — Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial has commenced enrollment. The first patient was treated by Joseph Cardenas, M.D., at Yuma Regional Hospital and the Heart, Lung and Vascular Center in Yuma, Ariz.

The TOBA II BTK study is a prospective, multi-center, single-arm study designed to investigate the safety and efficacy of the Tack Endovascular System in combination with standard balloon angioplasty in the popliteal and tibial arteries for the treatment of critical limb ischemia (CLI). The Tack Endovascular System is a new technology designed to repair dissections (or tears) in the artery wall that frequently occur as a complication of balloon angioplasty. The system allows physicians to repair these dissections while leaving a minimal amount of foreign material in the artery, reducing mechanical stress on the artery, and preserving future treatment options.

TOBA II BTK is the first known industry-sponsored pivotal clinical trial approved by the U.S. Food and Drug Administration to investigate a permanent vascular implant in arteries below the knee, according to Intact Vascular.

Cardenas stated, “One of our key goals when we perform angioplasty in patients with CLI is to restore blood flow to the foot, and keeping the treated arteries open over time is a major challenge. The Tack system is uniquely designed to repair dissections following angioplasty while minimizing arterial inflammation and leaving little foreign material behind. I believe this represents an ideal combination for maintaining long-term arterial patency.”

The TOBA II BTK study will be conducted at up to 50 global sites and will enroll 232 patients in total. Eligible patients will have diseased popliteal or tibial arteries treated with balloon angioplasty and have a dissection in the artery wall immediately following angioplasty.

Cardenas added, “The TOBA II BTK trial will provide us with valuable information about this very promising technology designed to optimize angioplasty results in CLI. We are thrilled to be the first center to begin enrollment in this important study.”

Intact Vascular is also sponsoring the TOBA II and TOBA III studies. TOBA II is investigating the combination of the Tack Endovascular System with both uncoated angioplasty balloons and the Bard Lutonix Drug-Coated Balloon in patients with superficial femoral and popliteal artery disease. TOBA III is investigating the combination of the Tack Endovascular System with the Medtronic In.Pact Admiral Drug-Coated Balloon in a similar population.

For more information: www.intactvascular.com

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now